Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 27;13(1):66.
doi: 10.1186/s13023-018-0800-z.

European principles of inhibitor management in patients with haemophilia

P L F Giangrande  1   2 , C Hermans  3 , B O'Mahony  4   5 , P de Kleijn  6 , M Bedford  7 , A Batorova  8 , J Blatný  9 , K Jansone  4 ; European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD)
Collaborators, Affiliations
Review

European principles of inhibitor management in patients with haemophilia

P L F Giangrande et al. Orphanet J Rare Dis. .

Abstract

Background: In spite of recent major advances in the understanding and treatment of inhibitor development in patients with haemophilia, multidisciplinary management of many of these patients remains suboptimal and highly heterogenous across Europe.

Methods: Following a series of multidisciplinary meetings and a review of the literature, the European haemophilia community of health professionals and patients jointly defined practical optimum standards for ensuring and harmonizing treatment and care for patients with an inhibitor.

Results: Ten complementary principles for the management of inhibitors in haemophilia have been developed, emphasizing the importance and benefits of a centralized, multidisciplinary, expert and holistic approach.

Conclusions: This document will serve as a benchmark to improve the multidisciplinary and practical management of patients with inhibitor. Implementation and adherence to each of these principles should have a major positive impact on the management and outcomes of patients developing an inhibitor.

Keywords: Bypassing agents; Factor IX; Factor VIII; Guidelines; Haemophilia; Immune tolerance; Inhibitors.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Competing interests

PG has received consultancy and/or lecture fees from Bayer, Biotest, CSL Behring, NovoNordisk, Pfizer and Shire within the last year. CH has received consultancy and/or lecture fees from Bayer, CSL Behring, NovoNordisk, Pfizer, Shire, SOBI, LFB, OctaPharma within the last year. MB is currently a member of the Roche/Chugai Haemophilia A Advisory Board and is in receipt of funding from Pfizer for an investigator-initiated research study. JB has received speaker’s fees and/or served as a consultant for NovoNordisk, Shire, Octapharma, Pfizer and Roche within last year. CH, BO’M, PdK, AB and KJ state that they have no competing interests to report.

References

    1. Soucie J, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol. 1998;59:288–294. doi: 10.1002/(SICI)1096-8652(199812)59:4<288::AID-AJH4>3.0.CO;2-I. - DOI - PubMed
    1. Astermark J. Overview of inhibitors. Semin Hematol. 2006;43(Suppl. 4):S3–S7. doi: 10.1053/j.seminhematol.2006.03.006. - DOI - PubMed
    1. Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood. 2013;122:1954–1962. doi: 10.1182/blood-2013-02-483263. - DOI - PubMed
    1. Colvin B, Astermark J, Fischer K, Gringeri A, Lassila R, et al. European principles of care. Haemophilia. 2008;14:361–374. doi: 10.1111/j.1365-2516.2007.01625.x. - DOI - PubMed
    1. Mancuso ME, Mannucci PM, Rocino A, Garagiola A, Tagliaferri A, Santagostino E. Source and purity of factor VIII products as risk factor for inhibitor development in patients with hemophilia A. J Thromb Haemost. 2012;10:781–790. doi: 10.1111/j.1538-7836.2012.04691.x. - DOI - PubMed